Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in children with cystic fibrosis aged 2–5 years (TIMBERLINE Trial VX21-121-105): a phase 3, open-label study

The Lancet Respiratory Medicine · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles